MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)*
Organization & Developments: Terns Pharmaceuticals
Parents
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)*
Children
2022: Terns Pharmaceuticals: Small 'Transpacific' Company With No Real Product Differentiation_seekingalpha.com
2022: Terns Pharmaceuticals: The Easy Money Has Been Made_ seekingalpha.com
2023: Terns Pharmaceuticals: Business Model Does Not Impress
2024: Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study
2024: Terns Pharmaceuticals: Another Potential GLP-1 Entrant
2024: Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst
2024: With 55% ownership, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) boasts of strong institutional backing
2025: Terns Pharma: I Don't See The Positioning
Jumps
Finance & Acquisitions: Terns Pharmaceuticals
Key People: Terns Pharmaceuticals